Audrey CHABRAT

Dr. Audrey CHABRAT

SGS (France), Arcueil, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HDHélène Doucet-Beaupré
Hélène Doucet-Beaupré
CGCatherine Gilbert
Catherine Gilbert
MPMarcos Schaan Profes
Marcos Schaan Profes
ACAudrey CHABRAT
Audrey CHABRAT
CPConsiglia Pacelli
Consiglia Pacelli
MLMartin Lévesque
Martin Lévesque
Significance: Degeneration of midbrain dopamine neurons is the main pathological hallmark of Parkinson’s disease. Identifying transcriptional programs that maintain these neurons in the adult brain will help us understand their specific vulnerability. Here, we show that the survival of dopaminergic neurons requires the ongoing action of LIM-homeodomain transcription factors Lmx1a and Lmx1b. We discovered an Lmx1a/b-dependent pathway maintaining mitochondrial functions in midbrain dopaminergic neurons. Accordingly, ablation of Lmx1a/b results in impaired respiratory chain activity, increased oxidative stress, and mitochondrial DNA damage and causes Lewy neurite-like pathology. Importantly, deletion of Lmx1a/b links metabolic impairment, α-synuclein inclusions, and progressive neuronal loss. Modulation of this pathway opens new strategies to slow down or prevent the death of vulnerable neurons in Parkinson’s disease.

7 December 2014 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
SPSimon J. Pelletier
Simon J. Pelletier
MLMarie Lagacé
Marie Lagacé
ISIsabelle St-Amour
Isabelle St-Amour
DADany Arsenault
Dany Arsenault
GCGiulia Cisbani
Giulia Cisbani
FCFrancesca Cicchetti
Francesca Cicchetti
The application of low-intensity direct current electric fields has been experimentally used in the clinic to treat a number of brain disorders, predominantly using transcranial direct current stimulation approaches. However, the cellular and molecular changes induced by such treatment remain largely unknown. Here, we tested various intensities of direct current electric fields (0, 25, 50, and 100V/m) in a well-controlled in vitro environment in order to investigate the responses of neurons, microglia, and astrocytes to this type of stimulation. This included morphological assessments of the cells, viability, as well as shape and fiber outgrowth relative to the orientation of the direct current electric field. We also undertook enzyme-linked immunosorbent assays and western immunoblotting to identify which molecular pathways were affected by direct current electric fields. In response to direct current electric field, neurons developed an elongated cell body shape with neurite outgrowth that was associated with a significant increase in growth associated protein-43. Fetal midbrain dopaminergic explants grown in a collagen gel matrix also showed a reorientation of their neurites towards the cathode. BV2 microglial cells adopted distinct morphological changes with an increase in cyclooxygenase-2 expression, but these were dependent on whether they had already been activated with lipopolysaccharide. Finally, astrocytes displayed elongated cell bodies with cellular filopodia that were oriented perpendicularly to the direct current electric field. We show that cells of the central nervous system can respond to direct current electric fields both in terms of their morphological shape and molecular expression of certain proteins, and this in turn can help us to begin understand the mechanisms underlying the clinical benefits of direct current electric field.

27 January 2017 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SKShabana Khan
Shabana Khan
SSSimon R.W. Stott
Simon R.W. Stott
ACAudrey CHABRAT
Audrey CHABRAT
ATAnna M. Truckenbrodt
Anna M. Truckenbrodt
BSBradley Spencer-Dene
Bradley Spencer-Dene
SASiew-Lan Ang
Siew-Lan Ang
Midbrain dopaminergic neurons are highly heterogeneous. They differ in their connectivity and firing patterns and, therefore, in their functional properties. The molecular underpinnings of this heterogeneity are largely unknown, and there is a paucity of markers that distinguish these functional subsets. In this paper, we report the identification and characterization of a novel subset of midbrain dopaminergic neurons located in the ventral tegmental area that expresses the basic helix-loop-helix transcription factor, Neurogenic Differentiation Factor-6 (NEUROD6). Retrograde fluorogold tracing experiments demonstrate thatNeurod6+midbrain dopaminergic neurons neurons project to two distinct septal regions: the dorsal and intermediate region of the lateral septum. Loss-of-function studies in mice demonstrate thatNeurod6and the closely related family memberNeurod1are both specifically required for the survival of this lateral-septum projecting neuronal subset during development. Our findings underscore the complex organization of midbrain dopaminergic neurons and provide an entry point for future studies of the functions of theNeurod6+subset of midbrain dopaminergic neurons.SIGNIFICANCE STATEMENTMidbrain dopaminergic neurons regulate diverse brain functions, including voluntary movement and cognitive and emotive behaviors. These neurons are heterogeneous, and distinct subsets are thought to regulate different behaviors. However, we currently lack the means to identify and modify gene function in specific subsets of midbrain dopaminergic neurons. In this study, we identify the transcription factor NEUROD6 as a specific marker for a novel subset of midbrain dopaminergic neurons in the ventral midbrain that project to the lateral septum, and we reveal essential roles forNeurod1andNeurod6in the survival of these neurons during development. Our findings highlight the molecular and anatomical heterogeneity of midbrain dopaminergic neurons and contribute to a better understanding of this functionally complex group of neurons.

16 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAudrey CHABRAT
Audrey CHABRAT
GBGuillaume Brisson
Guillaume Brisson
HDHélène Doucet-Beaupré
Hélène Doucet-Beaupré
CSCharleen Salesse
Charleen Salesse
MPMarcos Schaan Profes
Marcos Schaan Profes
MLMartin Lévesque
Martin Lévesque
Mesodiencephalic dopamine neurons play central roles in the regulation of a wide range of brain functions, including voluntary movement and behavioral processes. These functions are served by distinct subtypes of mesodiencephalic dopamine neurons located in the substantia nigra pars compacta and the ventral tegmental area, which form the nigrostriatal, mesolimbic, and mesocortical pathways. Until now, mechanisms involved in dopaminergic circuit formation remained largely unknown. Here, we show that Lmx1a, Lmx1b, and Otx2 transcription factors control subtype-specific mesodiencephalic dopamine neurons and their appropriate axon innervation. Our results revealed that the expression of Plxnc1, an axon guidance receptor, is repressed by Lmx1a/b and enhanced by Otx2. We also found that Sema7a/Plxnc1 interactions are responsible for the segregation of nigrostriatal and mesolimbic dopaminergic pathways. These findings identify Lmx1a/b, Otx2, and Plxnc1 as determinants of dopaminergic circuit formation and should assist in engineering mesodiencephalic dopamine neurons capable of regenerating appropriate connections for cell therapy.

1 October 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
GCG. Cisbani
G. Cisbani
JDJ. Drouin-Ouellet
J. Drouin-Ouellet
CGC. Gibrat
C. Gibrat
MSM. Saint-Pierre
M. Saint-Pierre
MLM. Lagacé
M. Lagacé
FCF. Cicchetti
F. Cicchetti

17 September 2022 in Viruses
Verified
Journal Article
Open access
PDF file
FBFrançois Briand
François Briand
VSValentin Sencio
Valentin Sencio
CRCyril Robil
Cyril Robil
SHSéverine Heumel
Séverine Heumel
LDLucie Deruyter
Lucie Deruyter
FTFrançois Trottein
François Trottein
Obese patients with non-alcoholic steatohepatitis (NASH) are prone to severe forms of COVID-19. There is an urgent need for new treatments that lower the severity of COVID-19 in this vulnerable population. To better replicate the human context, we set up a diet-induced model of obesity associated with dyslipidemia and NASH in the golden hamster (known to be a relevant preclinical model of COVID-19). A 20-week, free-choice diet induces obesity, dyslipidemia, and NASH (liver inflammation and fibrosis) in golden hamsters. Obese NASH hamsters have higher blood and pulmonary levels of inflammatory cytokines. In the early stages of a SARS-CoV-2 infection, the lung viral load and inflammation levels were similar in lean hamsters and obese NASH hamsters. However, obese NASH hamsters showed worse recovery (i.e., less resolution of lung inflammation 10 days post-infection (dpi) and lower body weight recovery on dpi 25). Obese NASH hamsters also exhibited higher levels of pulmonary fibrosis on dpi 25. Unlike lean animals, obese NASH hamsters infected with SARS-CoV-2 presented long-lasting dyslipidemia and systemic inflammation. Relative to lean controls, obese NASH hamsters had lower serum levels of angiotensin-converting enzyme 2 activity and higher serum levels of angiotensin II—a component known to favor inflammation and fibrosis. Even though the SARS-CoV-2 infection resulted in early weight loss and incomplete body weight recovery, obese NASH hamsters showed sustained liver steatosis, inflammation, hepatocyte ballooning, and marked liver fibrosis on dpi 25. We conclude that diet-induced obesity and NASH impair disease recovery in SARS-CoV-2-infected hamsters. This model might be of value for characterizing the pathophysiologic mechanisms of COVID-19 and evaluating the efficacy of treatments for the severe forms of COVID-19 observed in obese patients with NASH.